ACE Inhibitors, ARBs & Creatinine

ACE inhibitors and ARBs are among the most important medications in cardiovascular and renal medicine. They reduce mortality in heart failure with reduced ejection fraction, slow the progression of diabetic nephropathy, and reduce proteinuria in CKD. They also reliably raise creatinine when started — and that creatinine rise is frequently misinterpreted as a reason to stop.

The creatinine rise is not a sign of kidney injury. It is the intended hemodynamic effect of the medication. Understanding why it happens — and what it means — is the difference between protecting a patient's kidneys long-term and reflexively stopping a medication that was doing exactly what it was supposed to do.

The clinical question is not "did the creatinine go up?" It almost always does. The question is "how much did it go up, and is there a reason it went up more than expected?"

To understand why ACE inhibitors and ARBs raise creatinine, you need to understand the glomerular hemodynamics they affect. The glomerulus has two arterioles: the afferent arteriole, which brings blood in, and the efferent arteriole, which carries blood out. The pressure gradient across the glomerular capillary — intraglomerular pressure — drives filtration and determines GFR.

Angiotensin II preferentially constricts the efferent arteriole. This efferent constriction maintains intraglomerular pressure and GFR when renal perfusion pressure is reduced — for example, in heart failure, volume depletion, or renal artery stenosis. It is a compensatory mechanism that preserves filtration at the cost of elevated intraglomerular pressure.

ACE inhibitors block the conversion of angiotensin I to angiotensin II. ARBs block the angiotensin II receptor directly. Both reduce efferent arteriolar tone, lower intraglomerular pressure, and reduce GFR — which raises creatinine. This is not tubular injury. The tubules are intact. The kidney is filtering less because the driving pressure has been reduced.

The long-term benefit of this mechanism is that chronically elevated intraglomerular pressure damages the glomerular basement membrane and accelerates CKD progression. Reducing intraglomerular pressure — even at the cost of a modest creatinine rise — slows this damage. The creatinine rise is the price of the protection.

The clinical threshold that guides management is a creatinine rise of 30% from baseline. A rise of up to 30% is expected, acceptable, and does not require stopping the medication. It reflects the intended hemodynamic effect and is associated with the long-term renal protective benefit.

A rise greater than 30% warrants holding the medication and investigating why the rise was excessive. The most common reason is volume depletion — the patient is dehydrated, on aggressive diuretics, or has had poor oral intake, and the kidney is already relying heavily on angiotensin II to maintain perfusion. Removing that compensatory mechanism in a volume-depleted patient produces a larger creatinine rise than in a euvolemic patient.

Other causes of an excessive creatinine rise include bilateral renal artery stenosis (the classic contraindication), concurrent nephrotoxin use (NSAIDs, contrast, aminoglycosides), and acute illness that reduces effective arterial blood volume (sepsis, decompensated heart failure, hepatorenal syndrome).

The 30% threshold applies to a stable baseline creatinine. If the creatinine was already rising before the medication was started — for example, in a patient with an acute illness — the rise cannot be attributed to the ACE inhibitor or ARB alone.

Bilateral renal artery stenosis (RAS) — or stenosis of a solitary functioning kidney — is the most important contraindication to ACE inhibitors and ARBs. In this condition, both kidneys are underperfused due to fixed stenosis of the renal arteries. The kidneys compensate by maximally activating the renin-angiotensin system, relying on angiotensin II-mediated efferent constriction to maintain intraglomerular pressure and GFR.

When an ACE inhibitor or ARB is given to a patient with bilateral RAS, the compensatory mechanism is removed entirely. Intraglomerular pressure falls precipitously, GFR drops dramatically, and creatinine rises acutely — often within days of starting the medication. The presentation is a dramatic, rapid creatinine rise that is disproportionate to the dose and does not stabilize at a new plateau.

Clinical clues to bilateral RAS include hypertension that is difficult to control despite multiple agents, flash pulmonary edema (acute pulmonary edema without clear precipitant), asymmetric kidney sizes on imaging, and a history of peripheral vascular disease or atherosclerosis. Renal artery duplex ultrasound or CT angiography can confirm the diagnosis.

If bilateral RAS is suspected, ACE inhibitors and ARBs should be avoided. Nephrology or vascular surgery referral is appropriate for evaluation of revascularization.

When starting or uptitrating an ACE inhibitor or ARB, creatinine and potassium should be checked within 1–2 weeks. This is the window when the hemodynamic effect is established and any excessive rise will be apparent. In stable patients on a chronic dose, annual monitoring is generally sufficient unless there is an intercurrent illness or medication change.

If the medication was held for a creatinine rise greater than 30%, the decision to restart depends on whether the cause of the excessive rise has been identified and corrected. Volume depletion corrected? Nephrotoxin removed? Acute illness resolved? If so, restarting at a lower dose with closer monitoring is reasonable. If the cause was bilateral RAS or the creatinine rise was severe and unexplained, permanent discontinuation and nephrology referral are appropriate.

Hyperkalemia is often a more pressing reason to hold an ACE inhibitor or ARB than creatinine. Both medications reduce aldosterone, which is the primary driver of potassium excretion in the collecting duct. In patients with CKD, diabetes, or concurrent use of potassium-sparing diuretics or mineralocorticoid receptor antagonists, hyperkalemia can develop rapidly. Potassium above 5.5 mEq/L warrants holding or reducing the dose. Potassium above 6.0 mEq/L requires stopping and treating.

The newer potassium binders — patiromer and sodium zirconium cyclosilicate — have made it possible to continue ACE inhibitors and ARBs in patients who previously had to stop due to hyperkalemia. In patients with HFrEF or diabetic nephropathy where RAAS blockade provides significant benefit, these agents can enable continuation of a medication that would otherwise need to be stopped.